Proposed Indication: Alcoholic hepatitis (AH)
Proposed Indication: COVID-19 Associated Acute Liver or Kidney Injury
Proposed Indication: Nonalcoholic steatohepatitis (NASH)
Proposed Indication: Postoperative pain
Proposed Indication: Attention-deficit hyperactivity disorder (ADHD)
*Phase III study conducted in Taiwan. Approved in Taiwan as Methydur Sustained Release Capsules. Not approved in any other country.